Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients

Abstract Background Herpes zoster (HZ) infection of hematopoietic stem cell transplant (HSCT) patients is clinical concern. Vaccination could help restore immunity to varicella virus (VZV); however, temporal changes in immunogenicity and safety live HZ vaccines after HSCT still unclear. The aim this study was elucidate the vaccine according time since determine optimal timing vaccination. Methods Live administered 2–5 years or > 5 post-HSCT. Control groups comprised with a hematologic malignancy who received cytotoxic chemotherapy healthy volunteers. Humoral cellular were measured using glycoprotein enzyme-linked immunosorbent assay (gpELISA) an interferon-γ (IFN-γ) immunospot (ELISPOT) assay. Vaccine-related adverse events also monitored. Results Fifty-six (41 group 15 group) along 30 volunteers enrolled. geometric mean fold rises (GMFRs) humoral immune responses year groups, volunteer group, comparable significantly higher than that (3.15, 95% CI [1.96–5.07] vs 5.05, [2.50–10.20] 2.97, [2.30–3.83] 1.42, [1.08–1.86]). GMFR highest lowest group. No subject suffered clinically significant reactivation VZV within follow-up period. Conclusion Our findings demonstrate immunogenic safe when 2